https://www.ablitherapeutics.com/news/rss en-us Equisolve Investor Relations Suite https://www.ablitherapeutics.com/news/detail/9652/abli-therapeutics-appoints-industry-veteran-dr-rachelle-s-doody-to-its-board-of-directors Wed, 06 May 26 00:00:00 -0400 https://www.ablitherapeutics.com/news/detail/9652/abli-therapeutics-appoints-industry-veteran-dr-rachelle-s-doody-to-its-board-of-directors https://d1io3yog0oux5.cloudfront.net/_51206d3f86ed5409faf396c5b64af9fe/ablitherapeutics/files/ABLi_Needham_041626.mp4 Thu, 16 Apr 26 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/_51206d3f86ed5409faf396c5b64af9fe/ablitherapeutics/files/ABLi_Needham_041626.mp4 https://www.ablitherapeutics.com/events/detail/20260310-citizens-life-sciences-conference-webcast Tue, 10 Mar 26 00:00:00 -0400 https://www.ablitherapeutics.com/events/detail/20260310-citizens-life-sciences-conference-webcast https://www.ablitherapeutics.com/news/detail/9643/abli-therapeutics-to-present-at-the-citizens-life-sciences-conference Thu, 05 Mar 26 00:00:00 -0500 https://www.ablitherapeutics.com/news/detail/9643/abli-therapeutics-to-present-at-the-citizens-life-sciences-conference https://www.ablitherapeutics.com/news/detail/9639/abli-therapeutics-announces-publication-of-the-final-results-from-the-phase-2-201-trial-evaluating-risvodetinib-for-the-treatment-of-parkinsons-disease Fri, 20 Feb 26 00:00:00 -0500 https://www.ablitherapeutics.com/news/detail/9639/abli-therapeutics-announces-publication-of-the-final-results-from-the-phase-2-201-trial-evaluating-risvodetinib-for-the-treatment-of-parkinsons-disease https://d1io3yog0oux5.cloudfront.net/_0c6316cb829ca1f8f34312b0979cf5a5/ablitherapeutics/db/1015/9638/pdf/012726+ABLI+MJFF+COLLABORATION-FINAL.pdf Tue, 27 Jan 26 00:00:00 -0500 https://d1io3yog0oux5.cloudfront.net/_0c6316cb829ca1f8f34312b0979cf5a5/ablitherapeutics/db/1015/9638/pdf/012726+ABLI+MJFF+COLLABORATION-FINAL.pdf https://parkinsonsnewstoday.com/news/deal-advances-new-pet-tracer-test-risvodetinib-parkinsons/ Thu, 08 Jan 26 00:00:00 -0500 https://parkinsonsnewstoday.com/news/deal-advances-new-pet-tracer-test-risvodetinib-parkinsons/ https://d1io3yog0oux5.cloudfront.net/_0c6316cb829ca1f8f34312b0979cf5a5/ablitherapeutics/db/1015/9633/pdf/2026-01-05+--+ABLI+--+Strategic+Collab+--+FINAL.pdf Mon, 05 Jan 26 00:00:00 -0500 https://d1io3yog0oux5.cloudfront.net/_0c6316cb829ca1f8f34312b0979cf5a5/ablitherapeutics/db/1015/9633/pdf/2026-01-05+--+ABLI+--+Strategic+Collab+--+FINAL.pdf https://www.ablitherapeutics.com/news/detail/9632/exploring-risvodetinib-in-phase-2-trial-for-untreated-parkinson-disease Thu, 09 Oct 25 00:00:00 -0400 https://www.ablitherapeutics.com/news/detail/9632/exploring-risvodetinib-in-phase-2-trial-for-untreated-parkinson-disease https://d1io3yog0oux5.cloudfront.net/_0c6316cb829ca1f8f34312b0979cf5a5/ablitherapeutics/db/1015/9613/pdf/2025-10-09+--+ABLI+--+Final+Ph2+Risvodetinib+Data+in+PD+--+FINAL.pdf Thu, 09 Oct 25 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/_0c6316cb829ca1f8f34312b0979cf5a5/ablitherapeutics/db/1015/9613/pdf/2025-10-09+--+ABLI+--+Final+Ph2+Risvodetinib+Data+in+PD+--+FINAL.pdf